175 related articles for article (PubMed ID: 21402550)
1. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3.
Lancioni CL; Mahan CS; Johnson DF; Walusimbi M; Chervenak KA; Nalukwago S; Charlebois E; Havlir D; Mayanja-Kizza H; Whalen CC; Boom WH
J Infect Dis; 2011 Apr; 203(7):992-1001. PubMed ID: 21402550
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
[TBL] [Abstract][Full Text] [Related]
3. T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
da Silva TP; Giacoia-Gripp CB; Schmaltz CA; Sant Anna FM; Rolla V; Morgado MG
PLoS One; 2013; 8(6):e66095. PubMed ID: 23840403
[TBL] [Abstract][Full Text] [Related]
4. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP
J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475
[TBL] [Abstract][Full Text] [Related]
5. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.
Ravimohan S; Tamuhla N; Nfanyana K; Steenhoff AP; Letlhogile R; Frank I; MacGregor RR; Gross R; Weissman D; Bisson GP
Clin Infect Dis; 2016 Mar; 62(6):795-803. PubMed ID: 26611774
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.
Toossi Z; Funderburg NT; Sirdeshmuk S; Whalen CC; Nanteza MW; Johnson DF; Mayanja-Kizza H; Hirsch CS
J Infect Dis; 2013 Jun; 207(12):1841-9. PubMed ID: 23479321
[TBL] [Abstract][Full Text] [Related]
7. The effect of interrupted anti-retroviral treatment on the reconstitution of memory and naive T cells during tuberculosis treatment in HIV patients with active pulmonary tuberculosis.
Nalukwago S; Lancioni CL; Oketcho JB; Canaday DHE; Boom WH; Ojok L; Mayanja-Kizza H
Afr Health Sci; 2017 Dec; 17(4):954-962. PubMed ID: 29937865
[TBL] [Abstract][Full Text] [Related]
8. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
9. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
[TBL] [Abstract][Full Text] [Related]
10. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.
Brust JCM; Shah NS; Mlisana K; Moodley P; Allana S; Campbell A; Johnson BA; Master I; Mthiyane T; Lachman S; Larkan LM; Ning Y; Malik A; Smith JP; Gandhi NR
Clin Infect Dis; 2018 Apr; 66(8):1246-1253. PubMed ID: 29293906
[TBL] [Abstract][Full Text] [Related]
11. Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.
Ku NS; Oh JO; Shin SY; Kim SB; Kim HW; Jeong SJ; Han SH; Song YG; Kim JM; Choi JY
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):226-30. PubMed ID: 22881387
[TBL] [Abstract][Full Text] [Related]
12. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.
Serrano-Villar S; Sainz T; Lee SA; Hunt PW; Sinclair E; Shacklett BL; Ferre AL; Hayes TL; Somsouk M; Hsue PY; Van Natta ML; Meinert CL; Lederman MM; Hatano H; Jain V; Huang Y; Hecht FM; Martin JN; McCune JM; Moreno S; Deeks SG
PLoS Pathog; 2014 May; 10(5):e1004078. PubMed ID: 24831517
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.
Komati S; Shaw PA; Stubbs N; Mathibedi MJ; Malan L; Sangweni P; Metcalf JA; Masur H; Hassim S
AIDS; 2010 Jul; 24(12):1849-55. PubMed ID: 20622529
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Mahan CS; Walusimbi M; Johnson DF; Lancioni C; Charlebois E; Baseke J; Chervenak KA; Mugerwa RD; Havlir DV; Mayanja-Kizza H; Whalen CC; Boom WH;
PLoS One; 2010 Feb; 5(2):e9138. PubMed ID: 20179751
[TBL] [Abstract][Full Text] [Related]
15. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
16. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
17. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
18. Short-term antiretroviral therapy fails to reduce the expanded activated CCR5-expressing CD4+ T lymphocyte population or to restore the depleted naive population in chronically HIV-infected individuals with active pulmonary tuberculosis.
Kabue JP; de Swardt D; de Beer C; Glashoff RH
AIDS Res Hum Retroviruses; 2013 May; 29(5):769-77. PubMed ID: 23259904
[TBL] [Abstract][Full Text] [Related]
19. Impact of antiretroviral and tuberculosis therapies on CD4
Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; La Manna MP; Orlando V; Pinnetti C; Sampaolesi A; Antinori A; Caccamo N; Goletti D
Immunol Lett; 2018 Jun; 198():33-43. PubMed ID: 29635002
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
